Zobrazit minimální záznam

Serum Metabolite Biomarkers for Pancreatic Tumors: Neuroendocrine and Pancreatic Ductal Adenocarcinomas-A Preliminary Study

dc.contributor.authorSkubisz, Karolina
dc.contributor.authorDąbkowski, Krzysztof
dc.contributor.authorSamborowska, Emilia
dc.contributor.authorStarzyńska, Teresa
dc.contributor.authorDeskur, Anna
dc.contributor.authorAmbrożkiewicz, Filip
dc.contributor.authorKarczmarski, Jakub
dc.contributor.authorRadkiewicz, Mariusz
dc.contributor.authorKusnierz, Katarzyna
dc.contributor.authorKos-Kudła, Beata
dc.contributor.authorSulikowski, Tadeusz
dc.contributor.authorCybula, Patrycja
dc.contributor.authorPaziewska, Agnieszka
dc.date.accessioned2023-07-11T13:10:23Z
dc.date.available2023-07-11T13:10:23Z
dc.date.issued2023
dc.identifier.urihttps://hdl.handle.net/20.500.14178/1974
dc.description.abstractBACKGROUND: Pancreatic cancer is the most common pancreatic solid malignancy with an aggressive clinical course and low survival rate. There are a limited number of reliable prognostic biomarkers and a need to understand the pathogenesis of pancreatic tumors; neuroendocrine (PNET) and pancreatic ductal adenocarcinomas (PDAC) encouraged us to analyze the serum metabolome of pancreatic tumors and disturbances in the metabolism of PDAC and PNET. METHODS: Using the AbsoluteIDQ((R)) p180 kit (Biocrates Life Sciences AG, Innsbruck, Austria) with liquid chromatography-mass spectrometry (LC-MS), we identified changes in metabolite profiles and disrupted metabolic pathways serum of NET and PDAC patients. RESULTS: The concentration of six metabolites showed statistically significant differences between the control group and PDAC patients (p.adj < 0.05). Glutamine (Gln), acetylcarnitine (C2), and citrulline (Cit) presented a lower concentration in the serum of PDAC patients, while phosphatidylcholine aa C32:0 (PC aa C32:0), sphingomyelin C26:1 (SM C26:1), and glutamic acid (Glu) achieved higher concentrations compared to serum samples from healthy individuals. Five of the tested metabolites: C2 (FC = 8.67), and serotonin (FC = 2.68) reached higher concentration values in the PNET serum samples compared to PDAC, while phosphatidylcholine aa C34:1 (PC aa C34:1) (FC = -1.46 (0.68)) had a higher concentration in the PDAC samples. The area under the curves (AUC) of the receiver operating characteristic (ROC) curves presented diagnostic power to discriminate pancreatic tumor patients, which were highest for acylcarnitines: C2 with AUC = 0.93, serotonin with AUC = 0.85, and PC aa C34:1 with AUC = 0.86. CONCLUSIONS: The observations presented provide better insight into the metabolism of pancreatic tumors, and improve the diagnosis and classification of tumors. Serum-circulating metabolites can be easily monitored without invasive procedures and show the present clinical patients' condition, helping with pharmacological treatment or dietary strategies.en
dc.language.isoen
dc.relation.urlhttps://doi.org/10.3390/cancers15123242
dc.rightsCreative Commons Uveďte původ 4.0 Internationalcs
dc.rightsCreative Commons Attribution 4.0 Internationalen
dc.titleSerum Metabolite Biomarkers for Pancreatic Tumors: Neuroendocrine and Pancreatic Ductal Adenocarcinomas-A Preliminary Studyen
dcterms.accessRightsopenAccess
dcterms.licensehttps://creativecommons.org/licenses/by/4.0/legalcode
dc.date.updated2023-10-02T06:17:30Z
dc.subject.keywordSerumen
dc.subject.keywordMetaboliteen
dc.subject.keywordBiomarkersen
dc.subject.keywordforen
dc.subject.keywordTumorsen
dc.subject.keywordNeuroendocrineen
dc.subject.keywordPancreaticen
dc.subject.keywordDuctalen
dc.subject.keywordAdenocarcinomas-Aen
dc.subject.keywordPreliminaryen
dc.subject.keywordStudyen
dc.relation.fundingReferenceinfo:eu-repo/grantAgreement/EU/FP8/856620
dc.date.embargoStartDate2023-10-02
dc.type.obd73
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.identifier.doi10.3390/cancers15123242
dc.identifier.utWos001020678500001
dc.identifier.eidScopus2-s2.0-85164034336
dc.identifier.obd633187
dc.identifier.pubmed37370852
dc.subject.rivPrimary30000::30200::30204
dcterms.isPartOf.nameCancers
dcterms.isPartOf.issn2072-6694
dcterms.isPartOf.journalYear2023
dcterms.isPartOf.journalVolume15
dcterms.isPartOf.journalIssue12
uk.faculty.primaryId111
uk.faculty.primaryNameLékařská fakulta v Plznics
uk.faculty.primaryNameFaculty of Medicine in Pilsenen
uk.department.primaryId100012968318
uk.department.primaryNameBiomedicínské centrumcs
uk.department.primaryNameBiomedical Centeren
dc.description.pageRange1-24
dc.type.obdHierarchyCsČLÁNEK V ČASOPISU::článek v časopisu::původní článekcs
dc.type.obdHierarchyEnJOURNAL ARTICLE::journal article::original articleen
dc.type.obdHierarchyCode73::152::206en
uk.displayTitleSerum Metabolite Biomarkers for Pancreatic Tumors: Neuroendocrine and Pancreatic Ductal Adenocarcinomas-A Preliminary Studyen


Soubory tohoto záznamu

Thumbnail

Tento záznam se objevuje v následujících kolekcích

Zobrazit minimální záznam